 |
|
|
| |
Efficacy and Safety of the Fixed-Dose Combination Regimen of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) With or Without Ribavirin in Non-cirrhotic or Cirrhotic Participants With Chronic HCV GT1, 2, 3, 4, or 6 Infection (Parts A & B of C-CREST-1 & 2)
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-21 Amsterdam Netherlands
Eric Lawitz1; Eric M. Yoshida2; Maria Buti3; John M. Vierling4; Piero L. Almasio5; Savino Bruno6; Peter J. Ruane7; Tarek I. Hassanein8; Beat Muellhaupt9; Brian Pearlman10,11; Ligita Jancoriene12; Wei Gao13; Hsueh-Cheng Huang13; Aimee Shepherd13; Brynne Tannenbaum13; Doreen Fernsler13; Jerry J. Li13; Anjana Grandhi13; Hong Liu13; Mandy Su13; Frank Dutko13; Wendy W. Yeh13; Rebeca Plank13; Bach-Yen T. Nguyen13; Janice Wahl13; Eliav Barr13; Joan R. Butterton13
1Texas Liver Institute, University of Texas Health, San Antonio, TX, USA; 2University of British Columbia, Vancouver, BC, Canada; 3Hospital Universitario Valle Hebron, Barcelona, Spain; 4Baylor College of Medicine, Houston, TX, USA; 5U. O. di Gastroenterologia, Palermo, Italy; 6IRCCS Istituto Clinico Humanitas and Humanitas University, Rozzano, Italy; 7Ruane Medical and Liver Health Institute, Los Angeles, CA, USA; 8Southern California GI and Liver Centers, Coronado, CA, USA; 9University Hospital Zurich, Zurich, Switzerland; 10Atlanta Medical Center, Atlanta, GA, USA; 11Emory School of Medicine, Atlanta, GA, USA; 12Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania; 13Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
